Key Points
- In February, the U.S. Food and Drug Administration issued a "bright-line rule" redefining "biological products" under the Biologics Price Competition and Innovation Act (BPCIA) to include insulin and other...more
3/2/2020
/ Biologics ,
Biosimilars ,
BPCIA ,
Bright-Line Rule ,
Final Rules ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
PHSA ,
Purple Book